Kampanjeplan Novo Nordisk A/S
Avansert tidsplan
Enkel graf
Om selskapet Novo Nordisk A/S
Novo Nordisk A/S, медицинская компания, занимается исследованиями, разработками, производством и маркетингом фармацевтической продукции по всему миру. Он работает в двух сегментах: лечение диабета и ожирения и биофармация. Сегмент лечения диабета и ожирения предоставляет продукты в области инсулинов, GLP-1 и родственных систем доставки, пероральных противодиабетических продуктов, ожирения и других хронических заболеваний. Сегмент биофармацевтических препаратов предлагает продукты для лечения гемофилии, нарушений роста и заместительной гормональной терапии. flere detaljer| IPO date | 1982-01-04 |
|---|---|
| ISIN | US6701002056 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | dkk |
| Див.доход ао | 2.49 |
| Дивиденд ао | 1.1 |
| Сайт | https://www.novonordisk.com |
| Цена ао | 71.73 |
| Prisendring per dag: | 0% (64.73) |
|---|---|
| Prisendring per uke: | +1.71% (63.64) |
| Prisendring per måned: | -14.71% (75.89) |
| Prisendring over 3 måneder: | -23.51% (84.62) |
| Prisendring over seks måneder: | -45.06% (117.81) |
| Prisendring per år: | -47.57% (123.45) |
| Prisendring over 3 år: | -43.08% (113.72) |
| Prisendring over 5 år: | +8.26% (59.79) |
| Prisendring siden begynnelsen av året: | -26.15% (87.65) |
|
|
Undervurdering
|
Effektivitet
|
|||||||||||||||||||||||||||||||||||||
Utbytte
|
Plikt
|
Vekstimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institusjoner | Volum | Dele, % |
|---|---|---|
| Jennison Associates LLC | 22527772 | 0.66 |
| Fisher Asset Management, LLC | 14129598 | 0.41 |
| Renaissance Technologies, LLC | 13849335 | 0.4 |
| Bank of America Corporation | 12975409 | 0.38 |
| FMR, LLC | 12663225 | 0.37 |
| Sarofim, Fayez & Co | 11814051 | 0.34 |
| Morgan Stanley | 10614811 | 0.31 |
| Loomis Sayles & Company, LP | 9003325 | 0.26 |
| Folketrygdfondet | 8631264 | 0.25 |
| Polen Capital Management, LLC | 7958444 | 0.23 |
| ETF | Dele, % | Lønnsomhet for året, % | Utbytte, % |
|---|---|---|---|
| Fidelity Growth Opportunities ETF | 0.45018 | -9.28 | 0.48881 |
| Fidelity New Millennium ETF | 0.32428 | -5.13 | 1.58241 |
| 0.39 | -7.21 | 1.03 |
| Veileder | Stillingstittel | Betaling | Fødselsår |
|---|---|---|---|
| Mr. Lars Fruergaard Jorgensen | President, CEO & Member of Management Board | 4.67M | 1966 (59 år) |
| Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board | 1.85M | 1971 (54 år) |
| Mr. Henrik Ehlers Wulff | Executive VP of Product Supply, Quality & IT and Member of the Management Board | 1.87M | 1970 (55 år) |
| Ms. Camilla Sylvest | Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board | 1.82M | 1972 (53 år) |
| Mr. Maziar Mike Doustdar | Executive VP of International Operations & Member of the Management Board | N/A | 1970 (55 år) |
| Mr. Douglas J. Langa | Executive VP of North America Operations & Member of Management Board | N/A | 1966 (59 år) |
| Mr. Ludovic Helfgott | Executive VP, Head of Rare Disease & Member of Management Board | N/A | 1974 (51 år) |
| Dr. Martin Holst Lange | Executive VP of Development & Member of the Management Board | 1.77M | 1970 (55 år) |
| Dr. Marcus Schindler Ph.D. | EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board | 1.77M | 1966 (59 år) |
| Ms. Tania Sabroe | Executive VP of Global People & Organisation and Member of Management Board | N/A | 1977 (48 år) |
Adresse: Denmark, Bagsvaerd, Novo Alle 1 - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.novonordisk.com
Nettsted: https://www.novonordisk.com
